NCT07045051 Glycemic/Insulinemic Effects of Fresh Mango as a Sugar Substitute in Realistic Breakfasts.
| NCT ID | NCT07045051 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ball State University |
| Condition | Healthy Participants |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2025-03-26 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2025-03-26 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Large blood sugar and insulin increases after meals high in table sugar are related to risk for diabetes and heart disease. Additionally, large increases in blood sugar may also negatively impact vascular health. Previous research suggests that mango consumed in small quantities has blood sugar-lowering properties, but the evidence of this within larger, more realistic meals is limited. The investigators want to understand if replacing table sugar (sucrose) with sugar from fresh mango (which also contains fiber and plant bioactives) will lead to more favorable blood sugar, insulin, and vascular responses after eating breakfast meals. The investigators will compare the postprandial glycemic, insulinemic, and vascular response to low and high glycemic meals sweetened with either fresh mango or sucrose.
Eligibility Criteria
Inclusion Criteria: * 18 - 45 years. * Body mass index between 18.5-35.0 kg/m2 * Not pregnant (females only) * Not postmenopausal (females only). * Not been diagnosed with cardiovascular disease. * Not been diagnosed with a cardiometabolic conditions (e.g., type 2 diabetes) * Not been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease). * Does not regularly take anti-inflammatory drugs (more than 2x week). * Does not use glucose-lowering drugs (e.g., metformin) * Does not use lipid-lowering drugs (e.g., statins) * Does not use tobacco products or any illicit drugs. * Does not have a pacemaker. * Can consume mango, wheat, gluten, and milk. * Can stay in a supine position in the dark for at least ten minutes. Exclusion Criteria: * Not between the ages of 18-45 * Body mass index \< 18.5 kg/m2 or \>35.0 kg/m2 * Pregnant (females only) * Postmenopausal status (females only). * Been diagnosed with cardiovascular disease. * Been diagnosed with a cardiometabolic conditions (e.g., type 2 diabetes) * Been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease). * Regularly take anti-inflammatory drugs (more than 2x week). * Uses glucose-lowering drugs (e.g., metformin) * Uses lipid-lowering drugs (e.g., statins) * Uses tobacco products or any illicit drugs. * Have a pacemaker. * Allergic to mango, wheat, gluten, and/or milk. * Unable to lay in supine position in the dark for at least ten minutes.
Contact & Investigator
Bryant Keirns, PhD
PRINCIPAL INVESTIGATOR
Ball State University
Frequently Asked Questions
Who can join the NCT07045051 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Healthy Participants. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07045051 currently recruiting?
Yes, NCT07045051 is actively recruiting participants. Contact the research team at bryant.keirns@bsu.edu for enrollment information.
Where is the NCT07045051 trial being conducted?
This trial is being conducted at Muncie, United States.
Who is sponsoring the NCT07045051 clinical trial?
NCT07045051 is sponsored by Ball State University. The principal investigator is Bryant Keirns, PhD at Ball State University. The trial plans to enroll 24 participants.